|
1
|
Chen F, Zhang GN, Lei W, Zhou SG, Zhang Y, Liu L, Jia Y, Xie RK, Tian XF, Guo J, Yang YB, Wang XF, Wu XM, Sun QJ, Zhou X, Lin Y, Zhang YZ, Ma JQ, Liu YX, Cheng YF, Chen JC, Qu QX, Du DM, Wang GY, Wang S, Ling YL, Wu DF, Zhang CF, Lang JH. Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study. Gynecol Oncol 2023; 178:8-13. [PMID: 37734188 DOI: 10.1016/j.ygyno.2023.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 08/06/2023] [Accepted: 09/10/2023] [Indexed: 09/23/2023]
Abstract
BACKGROUND We previously reported that REBACIN effectively eliminates persistent high-risk human papillomavirus (hrHPV) infection. Here, we conducted a prospective multicenter cohort study to evaluate the safety and effectiveness of REBACIN, taking into account factors such as specific hrHPV subtype and patient's age. METHODS According to inclusion/exclusion criteria and participant willingness, 3252 patients were divided into REBACIN group while 249 patients into control group. Patients in REBACIN group received one course treatment of intravaginal administration of REBACIN while no treatment in control group. After drug withdrawal, participants in both groups were followed up. RESULTS The clearance rate of persistent hrHPV infection in REBACIN group was 60.64%, compared to 20.08% in control group. Specifically, the clearance rates for single-type infection of HPV16 or HPV18 were 70.62% and 69.23%, respectively, which was higher than that of HPV52 (59.04%) or HPV58 (62.64%). In addition, the single, double, and triple/triple+ infections had a clearance rate of 65.70%, 53.31%, and 38.30%, respectively. Moreover, 1635 patients under 40 years old had a clearance rate of 65.14%, while it was 55.08% for 1447 patients over 40 years old. No serious adverse effects were found. CONCLUSION This study confirmed that REBACIN can effectively and safely eliminate persistent hrHPV infection, which the clearance rate of HPV16/18 is higher than that of HPV52/58, the clearance rate of single-type infection is higher than that of multiple-type infections, and the clearance rate in young patients is higher than that in elder patients, providing a guidance for REBACIN application in clearing hrHPV persistent infection in real-world settings. CLINICAL TRIAL REGISTRATION Chinese Clinical Trial Registry Registration Number: ChiCTR1800015617 http://www.chictr.org.cn/showproj.aspx?proj=26529 Date of Registration: 2018-04-11.
Collapse
Affiliation(s)
- Fei Chen
- National Clinical Research Center for Obstetric & Gynecologic Diseases, and Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | | | - Wei Lei
- West China Second University Hospital, Sichuan University, Chengdu, China
| | - Shu-Guang Zhou
- Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, China
| | - Ying Zhang
- The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Lin Liu
- The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Ying Jia
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Rong-Kai Xie
- Xinqiao Hospital Army Medical University, Chongqing, China
| | | | - Jie Guo
- The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Yue-Bo Yang
- The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Xue-Feng Wang
- The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| | - Xiao-Mei Wu
- The First People's Hospital of Yunnan Province, Kunming, China
| | - Qi-Jian Sun
- First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Xu Zhou
- The Second Hospital of Jilin University, Changchun, China
| | - Yang Lin
- The Second Hospital of Jilin University, Changchun, China
| | | | - Jun-Qi Ma
- The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Yu-Xiu Liu
- China-Mongolia Hospital of Ulanqab, Ulanqab, China
| | - Yi-Fan Cheng
- The Women's Hospital School of Medicine Zhejiang University, Hangzhou, China
| | - Jian-Cui Chen
- Fujian Provincial Maternal and Child Health Care Hospital, Fuzhou, China
| | - Quan-Xin Qu
- Tianjin First Central Hospital, Tianjin, China
| | - Dong-Mei Du
- Key Laboratory of Protein Engineering and Drug Development of Hainan, Haikou, China
| | - Gui-Yu Wang
- Key Laboratory of Protein Engineering and Drug Development of Hainan, Haikou, China
| | - Sheng Wang
- Key Laboratory of Protein Engineering and Drug Development of Hainan, Haikou, China
| | - Yu-Li Ling
- Key Laboratory of Protein Engineering and Drug Development of Hainan, Haikou, China
| | | | | | - Jing-He Lang
- National Clinical Research Center for Obstetric & Gynecologic Diseases, and Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
| |
Collapse
|
|
2
|
Carlier PR, Du DM, Han YF, Liu J, Perola E, Williams ID, Pang YP. Dimerization of an Inactive Fragment of Huperzine A Produces a Drug with Twice the Potency of the Natural Product This work was supported by the Research Grants Council of Hong Kong (HKUST6156/97M), the Biotechnology Research Institute (HKUST), the Mayo Foundation, and the Istituto Pasteur Fondazione Cenci Bolognetti (E.P.). We thank Prof. X. C. Tang (Shanghai Institute of Materia Medica) for a gift of (-)-1. Angew Chem Int Ed Engl 2000; 39:1775-1777. [PMID: 10934357 DOI: 10.1002/(sici)1521-3773(20000515)39:10<1775::aid-anie1775>3.0.co;2-q] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- PR Carlier
- Department of Chemistry and Molecular Neuroscience Center Hong Kong University of Science and Technology Clear Water Bay, Kowloon (Hong Kong)
| | | | | | | | | | | | | |
Collapse
|
|
3
|
Abstract
Hybrid acetylcholinesterase inhibitors composed of a key fragment of huperzine A and an intact tacrine unit were prepared. The syntheses are quite direct, proceeding in a maximum of 4 linear steps from commercially available starting materials. The optimum hybrid inhibitor (+/-)-9g is 13-fold more potent than (-)-huperzine A, and 25-fold more potent than tacrine.
Collapse
Affiliation(s)
- P R Carlier
- Department of Chemistry, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon.
| | | | | | | | | |
Collapse
|